Resektable Lebermetastasen: Welche Modalität? ……………………………………………………………………………………………
P=0,007 Median OS: 47 vs 36 Monate Evidenzgrad IV Adjuvante Chemotherapie Stadium IV - 5-FU Analyse von Kohortenstudien Parks, J Am Coll Surg 2007 …...
Adjuvante Chemotherapie Stadium IV - 5-FU DFSOS n=173 (stopped prematurely, ITT: 171) Prim. EP: DFS (20% Unterschied im 2J. ÜL) Sek. EP: OS, safety 5 Yr DFS : 33.5 vs. 26.7% OR=0.66, p=0.028 Absolut. Benefit: 7% 5 Yr OS : 51.1 vs. 41.9% OR=0.73, p=0.13 Portier, J Clin Oncol 2006
Chemotherapie bei resektablen Metastasen ………………………………………………………………………………………………….………………
Perioperative Chemotherapie präOP: keine Therapie begonnen: 11 Pat. 6% alle 6 Zyklen absolviert: 78% …………………………………………………………………………………..…………………… …... Effektivität der Chemotherapie: CR 4%, PR 40% // PD // 6% Tumorverkleinerung: median 45à30mm …...
Perioperative Komplikationen ……………………………………………………………………………………………………………………………………… Nordlinger et al., ASCO 2007
EORTC 40983: Resultate Eligible pts. Resected pts. …………………………………………………………………………………..………
N pts CT N pts Surgery % absolute difference in 3-year PFS Hazard Ratio (Confidence Interval) P-value All patients % (28.1% to 35.4%) 0.79 ( ) P=0.058 All eligible Patients % (28.1% to 36.2%) 0.77 ( ) P=0.041 All resected Patients % (33.2% to 42.4%) 0.73 ( ) P=0.025 EORTC 40983: PFS …………………………………………………………………………………..………